A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Monoclonal antibody 3S193 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Aug 2015 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
- 05 Feb 2015 Planned End Date changed from 1 Sep 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
- 13 Mar 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.